Buddy Roemer: Me, O...
Health Care: Drugs
Merck & Co Inc (MRK: NYSE)
$38.24 -0.18 | -0.46%
02/09/12 - 12:20 PM ET
3.89M / 16.16M
Vol / Avg. Vol:38.40 / 38.42
Open / Prev. Close:38.14 - 38.52
Today's Range:29.47 - 39.43
52 Wk Range:1.91%
Performance YTD:TheStreet Rating:
Portfolios with MRK
- Portfolio NameUser Type
- Userrusselw24
- UserO4 Investing
- UserNick's Portfolio
- ContributorRocket Stocks for the Week ...
- UserPersonal Account
- ContributorHighest-Yielding Drug Stocks
- Contributor7 Pharma Buys for 2012
- ContributorCredit Suisse's 14 Ultimate...
- Userralphd2
- UserBerliner
Latest MRK Headlines from TheStreet
- They Just Don't Get Merck!
02.05.12 | 09:02 am - Merck's Lower Tax Rate 02.04.12 | 09:02 am
- Depomed: After-Hours Trading 02.03.12 | 05:02 pm
- Gilead Wows With New Hep C Data, Boxing Out Poor 2012 Guidance 02.03.12 | 07:02 am
- Groundhog Snoozer: Dave's Daily 02.02.12 | 07:02 pm
- Disney, Pfizer: Dow Movers 02.02.12 | 04:02 pm
- Merck & Co.'s CEO Discusses Q4 2011 Results - Earnings Call Transcript 02.02.12 | 04:02 pm
- Stocks End Mixed as Bernanke Touts Stability of U.S. Economy 02.02.12 | 04:02 pm
- Dow Today: Merck (MRK) Lower 02.02.12 | 01:02 pm
- Merck's Risky Cost Cutting Move 02.02.12 | 12:02 pm
Press Releases for MRK
- Thomas E. Shenk To Retire From Merck's Board Of Directors - Business Wire 02.08.12 | 03:02 pm
- Merck Announces Top-Line Results Of TRA-2P Study Of Vorapaxar - Business Wire 02.07.12 | 08:02 am
- Merck Provides Update On Development Program For Suvorexant, An Investigational Orexin Receptor Antagonist For The Treatment Of Insomnia - Business Wire 02.06.12 | 08:02 am
- FDA Approves JANUMET® XR (sitagliptin And Metformin HCl Extended-release) For Type 2 Diabetes, Offering The Powerful Efficacy Of JANUMET® (sitagliptin/metformin HCl) Now Available With Once-Daily Convenience - Business Wire 02.02.12 | 02:02 pm
- Merck Announces Full-Year And Fourth-Quarter 2011 Financial Results - Business Wire 02.02.12 | 07:02 am
- Reminder: Merck To Hold 2011 Full-Year And Fourth-Quarter Sales And Earnings Conference Call On February 2 - Business Wire 01.26.12 | 08:01 am
- New FDA Approved Labeling For VYTORIN® (Ezetimibe/Simvastatin) Includes Results From The Study Of Heart And Renal Protection (SHARP) In Patients With Moderate To Severe Chronic Kidney Disease - Business Wire 01.25.12 | 08:01 am
- Merck To Present At The 30th Annual J.P. Morgan Healthcare Conference - Business Wire 01.09.12 | 08:01 am
- Merck To Present At Goldman Sachs 2012 Healthcare Event - Business Wire 01.04.12 | 08:01 am
- Merck And The ADAP Crisis Task Force Announce New Agreement To Improve Access And Care For People With HIV - Business Wire 12.21.11 | 11:12 am
Partner Headlines for MRK
- Forget Big Pharma, It's Time For A Biotech ETF - ETF News And Commentary - Zacks 02.09.12 | 10:02 am
- Company News for February 7, 2012 - Corporate Summary - Zacks 02.07.12 | 10:02 am
- Stock Market News for February 3, 2012 - Market News - Zacks 02.03.12 | 10:02 am
- The Zacks Analyst Blog Highlights: Cummins, Kellogg, Merck, Dow Chemical and International Paper - Press Releases - Zacks 02.03.12 | 09:02 am
- Mixed Earnings, Steady Jobless Claims - Analyst Blog - Zacks 02.02.12 | 10:02 am
- Ahead of Wall Street - February 2, 2012 - Ahead of Wall Street - Zacks 02.02.12 | 10:02 am
- Merck Beats on EPS, Guides In-Line - Analyst Blog - Zacks 02.02.12 | 10:02 am
- Earnings Preview For Merck 4Q 2011 - Seeking Alpha 02.01.12 | 09:02 am
- What Is A Moat? - Seeking Alpha 02.01.12 | 08:02 am
- 5 Stocks That Could Be Takeover Targets - Seeking Alpha 02.01.12 | 08:02 am
